Leerink Partnrs Weighs in on Repligen Co.'s Q2 2024 Earnings (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities researchers at Leerink Partnrs increased their Q2 2024 earnings per share estimates for shares of Repligen in a report released on Wednesday, May 1st. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will earn $0.33 per share for the quarter, up from their previous forecast of $0.31. The consensus estimate for Repligen's current full-year earnings is $1.46 per share. Leerink Partnrs also issued estimates for Repligen's Q3 2024 earnings at $0.40 EPS, Q4 2024 earnings at $0.46 EPS, FY2024 earnings at $1.48 EPS, Q1 2025 earnings at $0.44 EPS, Q2 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at $2.05 EPS.

Other equities research analysts have also issued research reports about the stock. KeyCorp increased their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. decreased their target price on Repligen from $230.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday. Finally, Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $195.70.

Repligen Stock Performance

Shares of RGEN stock traded up $0.74 during midday trading on Friday, hitting $167.05. The company had a trading volume of 454,939 shares, compared to its average volume of 541,123. The company's 50 day simple moving average is $181.40 and its 200 day simple moving average is $173.80. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The stock has a market cap of $9.33 billion, a price-to-earnings ratio of 665.27, a PEG ratio of 5.19 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.94% and a net margin of 2.44%. Repligen's revenue was down 17.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS.

Insider Transactions at Repligen

In related news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company's stock, valued at $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO James Bylund sold 4,373 shares of Repligen stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 over the last three months. Company insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Repligen

Large investors have recently bought and sold shares of the business. Retirement Systems of Alabama lifted its holdings in Repligen by 0.4% during the 4th quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company's stock valued at $11,693,000 after purchasing an additional 288 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company's stock worth $1,663,000 after buying an additional 159 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Repligen by 18,449.1% during the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company's stock worth $10,539,000 after buying an additional 58,299 shares during the period. American Century Companies Inc. boosted its holdings in shares of Repligen by 97.5% during the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company's stock worth $34,648,000 after buying an additional 107,570 shares during the period. Finally, Louisiana State Employees Retirement System acquired a new position in Repligen in the 4th quarter valued at about $2,625,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.